Free Trial

921,580 Shares in Becton, Dickinson and Company (NYSE:BDX) Bought by Nuveen LLC

Becton, Dickinson and Company logo with Medical background

Key Points

  • Nuveen LLC acquired 921,580 shares of Becton, Dickinson and Company, valued at approximately $211 million, marking a new position for the fund in the medical instruments supplier.
  • Recent SEC filings indicate that institutional investors own about 86.97% of Becton, Dickinson and Company's stock, highlighting strong institutional interest in the company.
  • Becton, Dickinson and Company announced a quarterly dividend of $1.04 per share, representing an annualized yield of 2.2%, with the dividend payment scheduled for September 30th.
  • Looking to export and analyze Becton, Dickinson and Company data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Nuveen LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 921,580 shares of the medical instruments supplier's stock, valued at approximately $211,097,000. Nuveen LLC owned 0.32% of Becton, Dickinson and Company at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock valued at $6,414,322,000 after buying an additional 1,259,750 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Becton, Dickinson and Company by 36.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock worth $2,751,187,000 after purchasing an additional 3,219,317 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Becton, Dickinson and Company by 10.8% during the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock valued at $1,567,654,000 after purchasing an additional 667,957 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Becton, Dickinson and Company by 7.6% during the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock valued at $1,012,649,000 after purchasing an additional 312,124 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC increased its holdings in shares of Becton, Dickinson and Company by 392.4% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 3,416,665 shares of the medical instruments supplier's stock valued at $775,139,000 after purchasing an additional 2,722,829 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. William Blair downgraded shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Bank of America downgraded Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target on the stock. in a report on Friday, May 2nd. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a report on Friday, August 8th. Finally, Morgan Stanley boosted their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a report on Monday. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $211.44.

Get Our Latest Report on BDX

Insider Buying and Selling

In other news, Director Claire Fraser sold 863 shares of the firm's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the transaction, the director owned 23,143 shares in the company, valued at approximately $4,450,398.90. This trade represents a 3.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,214 shares of company stock worth $579,206. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded up $0.84 on Friday, hitting $195.84. The company's stock had a trading volume of 1,283,498 shares, compared to its average volume of 2,667,726. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a market capitalization of $56.13 billion, a price-to-earnings ratio of 35.22, a price-to-earnings-growth ratio of 1.47 and a beta of 0.20. The stock's 50-day moving average is $177.75 and its two-hundred day moving average is $197.66. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter in the previous year, the business earned $3.50 earnings per share. The firm's revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Read More

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Should You Invest $1,000 in Becton, Dickinson and Company Right Now?

Before you consider Becton, Dickinson and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.

While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines